Skip to main content

Table 2 Incremental cost-effectiveness ratio (ICER) (assuming length of IV treatment for success and survival is 14 days)

From: Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species

Candidemia/invasive candidiasis

First-line treatment

Total cost

Incremental cost

Total life-years

Incremental life-years

ICER

All species

Fluconazole (ref.)

4229

-

6.52

-

-

Anidulafungin

6799

2570

7.23

0.70

3666

Micafungin

7171

2942

5.55

−0.98

−3011

Caspofungin

9211

4983

6.03

−0.49

−10,140

Candida albicans

Non-echinocandins (ref.)

13,972

-

5.97

-

-

Echinocandins

7175

−6797

7.39

1.42

−4796

Non-albicans

Non-echinocandins (ref.)

7043

-

4.56

-

-

Echinocandins

8469

1426

6.75

2.19

652

  1. Cost value is presented in 2015 US dollars